CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 90 enrolled
Drug / intervention
Cannabidiol +1 moredrug
Likely dose
Cannabidiol 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04387617
NCT04387617Phase 3Completed
CompareCT.gov

Effect of Cannabidiol Oil on Postoperative Pain After Ureteroscopy for Urinary Calculi

Mayo Clinic·interventional·Posted May 14, 2020·Updated Jan 18, 2023

In Brief

A Phase 3 clinical trial evaluating Cannabidiol and Placebo for Urinary Stone. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if CBD oil has any effect on decreasing postoperative pain control following ureteroscopy for urinary stone disease, and to determine if CBD oil has any effect in decreasing the amount of postoperative opioids (commonly used drug) used by patients after undergoing ureteroscopy for urinary stone disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Stone
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedMay 14, 2020
Enrollment StartFeb 15, 2021
Primary CompletionJan 31, 2022
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.1 years ago

Interventions

Cannabidioldrug

The product is a liquid formulation that will be prescribed at a dosage of 20 mg per day for a total of 3 days.

Placebodrug

The product is a liquid formulation placebo that will be prescribed at an equivalent volume as active drug for 3 days